Making waves in cardiovascular disease treatment

Beyond Biotech - the podcast from Labiotech

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.

This week, we have a conversation with the CEO of Cytokinetics, Robert Blum, about the company’s aficamten, its next-in-class cardiac myosin inhibitor, prior to results from a phase 3 clinical trial in obstructive hypertrophic cardiomyopathy.

00:54-02:32: About Cytokinetics
02:32-04:11: What are the current treatments for cardiovascular conditions?
04:11-05:44: About cardiovascular disease
05:44-08:59: What is aficamten?
08:59-09:12: How is it administered?
09:12-10:04: Where is aficamten on the path to commercialization?
10:04-12:06: What does this mean for patients?
12:06-12:42: What will you be presenting in Portugal?
12:42-16:06: Could aficamten have other applications?
16:06-16:50: What is CK-136?
16:50-18:02: What is omecamtiv mecarbil?
18:02-20:26: Cytokinetics’ business model

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Chapters

1. Making waves in cardiovascular disease treatment (00:00:00)

2. About Cytokinetics (00:00:54)

3. What are the current treatments for cardiovascular conditions? (00:02:32)

4. About cardiovascular disease (00:04:11)

5. What is aficamten?
 (00:05:44)

6. How is aficamten administered?
 (00:08:59)

7. Where is aficamten on the path to commercialization?
 (00:09:12)

8. What does this mean for patients?
 (00:10:04)

9. What will you be presenting in Portugal?
 (00:12:06)

10. Could aficamten have other applications?
 (00:12:42)

11. What is CK-136? (00:16:06)

12. What is omecamtiv mecarbil?
 (00:16:50)

13. Cytokinetics’ business model (00:18:02)